Expertise in
2
conditions

Dr. Jonathan S. Goldberg

Internal Medicine
Memorial Regional Hospital
3501 Johnson St, 
Hollywood, FL 
Accepting New Patients
Expertise in
2
conditions
Memorial Regional Hospital
3501 Johnson St, 
Hollywood, FL 

Overview

Jonathan Goldberg is a primary care provider, practicing in Internal Medicine in Hollywood, Florida.

Dr. Goldberg is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Chronic Inflammatory Response Syndrome (CIRS), Sepsis, Acute Kidney Failure, Gastrostomy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 9 clinical trials. Dr. Goldberg is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Hospital Affiliations

Memorial Regional Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Memorial Regional Hospital
3501 Johnson St, Hollywood, FL 33021
Other Locations
The Jewish Hospital-Mercy Health
4777 E Galbraith Rd, Cincinnati, OH 45236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 8 Less Clinical Trials

3 Total Publications

A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
Journal: Leukemia & lymphoma
Published: July 17, 2024
Similar Doctors
Expertise in
103
conditions
Dr. Charles B. Stone
Internal Medicine
Expertise in
103
conditions
Dr. Charles B. Stone
Internal Medicine
Before you request

Alexander Sandy Nininger State Veterans Nursing

8401 W Cypress Dr, 
Pembroke Pines, FL 
 (4.7 miles away)
954-985-4824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Stone is a primary care provider, practicing in Internal Medicine in Pembroke Pines, Florida. Dr. Stone is highly rated in 103 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Cirrhosis, Familial Hypertension, and Glucocorticoid-Remediable Aldosteronism. Dr. Stone is currently accepting new patients.

Expertise in
12
conditions
Dr. Leonard J. Hoenig
Internal Medicine
Expertise in
12
conditions
Dr. Leonard J. Hoenig
Internal Medicine

Office

601 N Flamingo Rd Ste 201, 
Pembroke Pines, FL 
 (10.0 miles away)
954-438-0077
Languages Spoken:
English, French, Hebrew, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Leonard Hoenig is a primary care provider, practicing in Internal Medicine in Pembroke Pines, Florida. Dr. Hoenig is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Hartnup Disease, Rhinophyma, Smallpox, and Spider Angioma. Dr. Hoenig is currently accepting new patients.

Expertise in
20
conditions
Dr. David F. Snipelisky
Internal Medicine
Expertise in
20
conditions
Dr. David F. Snipelisky
Internal Medicine

Cleveland Clinic Florida

2950 Cleveland Clinic Blvd, 
Weston, FL 
 (12.3 miles away)
954-659-5290
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Snipelisky is a primary care provider, practicing in Internal Medicine in Weston, Florida. Dr. Snipelisky is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Heart Failure, Cardiogenic Shock, Cardiac Amyloidosis, Heart Transplant, and Liver Transplant.

Frequently Asked Questions about Dr. Jonathan S. Goldberg

How do I make an appointment with Dr. Jonathan S. Goldberg?

You can book an appointment with Dr. Jonathan S. Goldberg by calling their office at 954-265-6959. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan S. Goldberg a top-rated expert for Chronic Inflammatory Response Syndrome (CIRS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan S. Goldberg is classified as an Advanced expert for Chronic Inflammatory Response Syndrome (CIRS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan S. Goldberg specialize in?

While Dr. Jonathan S. Goldberg is a Internal Medicine, they have specific expertise in Chronic Inflammatory Response Syndrome (CIRS), Sepsis, and Acute Kidney Failure. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Jonathan S. Goldberg participate in research or clinical trials?

Yes. Dr. Jonathan S. Goldberg has published 3 articles and abstracts on conditions like Chronic Inflammatory Response Syndrome (CIRS). You can view a list of Dr. Jonathan S. Goldberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan S. Goldberg accept my insurance?

Dr. Jonathan S. Goldberg accepts most major insurance plans, including Aetna and AvMed. We recommend calling the office directly at 954-265-6959 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldberg's expertise for a condition
ConditionClose
      View All 103 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile